Newsfeed

AHIP To Go On Offensive On Medicare Advantage

With Medicare Advantage (MA) facing huge financial difficulties due to lower rates and crippling government regulatory changes, AHIP, the health plan lobby, is underwriting a seven-figure lobbying and advertising campaign to call attention to the challenges, obtain higher rates, and explain the major benefits for Medicare enrollees.

Additional article: https://subscriber.politicopro.com/article/2024/08/top-health-insurance-group-outlines-plans-to-protect-medicare-advantage-00173713

(Some articles may require a subscription.)

#medicareadvantage

https://www.beckerspayer.com/payer/payers-plan-medicare-advantage-lobbying-blitz.html

Read More »

PhRMA Attacks FDA Licensing Affordability Proposal

PhRMA, the brand drug manufacturer lobby, is attacking the National Institutes of Health’s (NIH) proposal to tie its licensing process to drug affordability in the United States once products hit the market. The proposal would tie U.S. prices to those in other developed countries.

PhRMA argues that it would discourage collaboration by the private sector with NIH. “History demonstrates that placing unreasonable terms on licensing agreements diminishes willingness to engage in public-private partnership,” PhRMA said.

But there is nothing wrong with the government tying affordability to any collaboration with the government. So much of what the drug industry eventually markets is tied to government innovation and funding.  The proposal is not unlike march-in rights on patents, which is something to consider as well. It also ties to Medicare drug price negotiations.

Let’s remember: the drug market is not a free market and needs reform.

(Article may require a subscription.)

#drugpricing #nih #fda #branddrugmakers

https://insidehealthpolicy.com/inside-drug-pricing-daily-news/phrma-nih-s-plan-limit-price-licensing-will-chill-collaboration

Read More »

What Do Q2 Insurer Investor Calls Tell Us?

Q2 2024 investor calls are coming to a close and we see mixed results on the part of insurers. Some insurers, such as Cigna (commercial-dominate, Alignment Healthcare (Medicare Advantage (MA)- dominant), Clover Health (MA-dominant), and Oscar Health (Exchange-dominant), have bucked negative trends.

On the other hand, CVS Health, Humana and Centene have been hurt by Medicare and Medicaid rates and cost pressures.

United remains dominate, but also reported cost pressures and costs from the Change Healthcare cyberattacks.

Elevance Health appears to be performing among the best, growing its services line and mitigating government program pressures with strong commercial performance.

#healthplans #insurers #healthcare #earnings

https://www.fiercehealthcare.com/payers/medicaid-ma-headwinds-pressure-payers-q2-heres-look-how-major-companies-fared

Read More »

GOP On Attack On Questionable CMS Part D Demonstration

The GOP is on the attack over the Centers for Medicare and Medicaid Services’ (CMS) announcement of a demonstration project to stabilize 2025 Part D premiums. CMS hurriedly put together the demo after it saw huge increases in Part D premiums come in during the 2025 bid cycle. This was due to the Inflation Reduction Act’s (IRA) shifting of huge costs from the government to health plans and out-of-pocket cost reductions. CVS, the biggest standalone Part D plan, apparently recommended that CMS create the program, although one already exists in law covering just a piece of the benefit.

The conservative Paragon Health Institute says the program could cost $10 billion over three years to limit premiums by bailing out insurers. The IRA approach on Part D was flawed and the public will be hurt by high premiums, but I continue to feel the demo is extra-regulatory and extra-legal.

(Article may require a subscription.)

#partd #pdp #medicareadvantage #premiums #medicare #drugpricing

https://insidehealthpolicy.com/daily-news/conservative-pressure-against-cms-medicare-part-d-demo-mounts

Read More »

CVS Struggles Financially; Undertakes $2 Billion In Cost-Cutting

CVS slashed its full-year guidance in its Q2 investor call and has begun a multi-year initiative to generate as much as $2 billion in savings. CVS has been hit by very high utilization in its Medicare Advantage (MA) line and plans to shed about 10% of its Medicare lives in 2025. Its overall medical loss ratio (MLR) is about 90% through 1H 2024.

Its Aetna line is performing so poorly that it terminated its recently-hired Aetna president and CVS Health CEO Karen Lynch will take over day-to-day control. She formerly was president of the unit and knows it well. CVS missed its revenue target but exceeded its margin expectations with $1.8 billion in Q2. CVS’ MA line has negative margins now, but the benefit reductions and contraction it plans in 2025 will return it to 4% to 5% MA margins over time. Lynch also committed to vigorous education and defense of its pharmacy benefits manager.

Additional articles: https://www.fiercehealthcare.com/payers/cvs-ceo-karen-lynch-take-helm-aetna-amid-ongoing-utilization-spike and https://www.modernhealthcare.com/finance/cvs-health-earnings-aetna-president-brian-kane-ceo-karen-lynch and https://www.healthcaredive.com/news/aetna-president-out-cvs-medicare-advantage-woes/723513/ and https://www.beckerspayer.com/payer/cvs-second-half-of-2024-could-be-even-worse-for-medicare-advantage.html and https://www.beckerspayer.com/executive-moves/aetna-president-out-after-disappointing-financial-results.html and https://www.beckerspayer.com/payer/payers-pledge-defense-of-their-pbms.html

(Some articles may require a subscription.)

#medicareadvantage #partd #aetna #cvshealth

https://www.fiercehealthcare.com/payers/cvs-kicks-multiyear-2b-cost-cutting-effort

Read More »

Republicans Ask GAO If CMS’ Proposed Part D Premium Stabilization Program Is Legal

A group of House and Senate Republicans are asking the congressional Government Accountability Office (GAO) if the Centers for Medicare and Medicaid Services’ (CMS) proposed additional premium stabilization program for standalone Part D (PDP) plans is legal. CMS announced the creation of the program after it received bids that showed premiums would skyrocket despite some protections in the Inflation Reduction Act (IRA).

The Part D changes in the IRA were much touted as protecting consumers by lowering out-of-pocket (OOP) costs. It also shifted huge costs to plans. These changes were not adequately funded by the government and thus plans had to reduce benefits in other areas and increase premiums. CMS was caught flat-footed and quickly created the program recently to avoid an October Surprise during open enrollment. I have issues with whether CMS has the statutory authority to do this despite broad waiver authority. It will further deplete sparse Medicare funds.

The GOP lawmakers asked the GAO whether the new demo is consistent with the law, to investigate what budgetary analysis CMS did when developing the program, to determine the projected costs, and whether it meets budget neutrality requirements.

See my earlier blogs on this subject: https://www.healthcarelabyrinth.com/part-d-premium-woes-due-to-the-inflation-reduction-act/ and https://www.healthcarelabyrinth.com/will-democrats-be-victim-of-an-october-surprise-of-their-own-making/ .

(Article may require a subscription.)

#medicareadvantage #pdp #partd #cms #ira

https://insidehealthpolicy.com/daily-news/gop-asks-gao-whether-cms-part-d-premium-stabilization-demo-legal

Read More »

Another Devastating Piece From The Wall Street Journal On Medicare Advantage

Yet another piece from The Wall Street Journal (WSJ) is bound to generate huge attention on Capitol Hill and among regulators. In its latest expose on Medicare Advantage (MA) finances, WSJ finds that MA home visits’ diagnoses for risk adjustment generated $15 billion in extra pay from 2019 to 2021. WSJ says nurses are pushed to make diagnoses the patient does not have and such diagnoses are never treated by hospitals or physicians. A July article found that $50 billion in overpayments occurred from 2019 to 2021 tied to risk adjustment submissions not treated by healthcare providers.

I am a supporter of MA, but I have made the case that a small number of bad actors are generating a huge amount of overpayments and giving all plans a bad name. I have told plans to expect that the Centers for Medicare and Medicaid Services (CMS) will eventually bar health risk assessment visits as well as manual chart review submissions for encounter data. I think this is fair and reasonable. See my blog on the subject here: https://www.healthcarelabyrinth.com/will-cms-rein-in-risk-adjustment-submissions/.  And my related podcast here: https://www.healthcarelabyrinth.com/25-ma-plans-should-ready-for-changes-to-risk-adjustment-submissions/ .

WSJ article (needs subscription): https://www.wsj.com/health/healthcare/medicare-extra-payments-home-visits-diagnosis-057dca8b

Additional article: https://www.beckershospitalreview.com/care-coordination/insurers-push-diagnoses-during-at-home-visits-bringing-in-billions-wsj.html

(Some articles may require a subscription.)

#medicareadvantage #riskadjustment #radv #overpayments

https://www.beckerspayer.com/payer/medicare-advantage-plans-collect-billions-through-home-visits-wsj.html

Read More »

State Affordability Boards Taking On Drug Makers Where The Feds Have Failed

Frustrated by high drug prices and inadequate policy changes at the federal level (save for slow-moving Medicare drug price negotiations), states are setting up drug affordability boards that can have vast powers to reduce drug costs. This includes setting an upper limit for sales in their state for certain coverage and the uninsured. This is similar to the Medicare drug price negotiations.

Due to federal pre-emption, these boards only apply to commercial plans. Medicaid has a federal rebate law that allows for federal and state rebates. Medicare is not covered as private plans negotiate prices with drug makers through pharmacy benefits managers or directly. Under the self-insured employer ERISA law, employer groups appear to be able to opt in and thus this has been built into some state laws.

 So far, eleven states have approved establishing drug affordability boards, and about a dozen more are considering doing so. Drug makers are suing, claiming the boards are unconstitutional and override several federal laws and due process.

#drugpricing #ira #branddrugmakers #employercoverage #erisa

https://www.managedhealthcareexecutive.com/view/states-are-setting-up-affordability-boards-to-rein-in-drug-costs

Read More »

Cigna Exceeds Expectations for Q2

The Cigna Group reported Q2 earnings that exceeded expectations, driven by growth in its services business. Total revenue in Q2 was $60.5 billion, up 24.6% year over year. It reported $1.5 billion in net income, up 6%.

Cigna is more isolated from Medicare pressures (small line being sold) and Medicaid pressures (no line). Evernorth’s services revenue rose nearly 30% year over year to $49.5 billion. Pharmacy service revenues grew more than 41% to $26.6 billion. In great measure this was due to the migration of Centene from CVS Caremark to ESI.

CEO David Cordani also committed to more aggressive defense of the value of its pharmacy benefit manager, ESI.

In related news, Cigna says its GLP-1 weight-loss program has enrolled two million.

Additional articles: https://www.healthcaredive.com/news/cigna-aggressive-pharmacy-benefit-manager-defense/722638/ and https://www.beckerspayer.com/payer/cigna-posts-1-5b-profit-in-q2-2.html  and https://www.fiercehealthcare.com/payers/evernorth-drives-double-digit-revenue-growth-cigna-q2 and https://www.beckerspayer.com/payer/cignas-glp-1-program-enrolls-2-million.html

(Some articles may require a subscription.)

#healthplans #cigna

https://www.modernhealthcare.com/insurance/cigna-earnings-call-evernorth-health-services-revenue-growth-medicare-medicaid

Read More »

Humana Meets Expectations in Q2 But With Some Mixed News

Medicare Advantage (MA)-dominant Humana released its Q2 2024 results. It had $679 million in profit for the second quarter, down from $959 million a year ago. It had $29.5 billion in revenue for the quarter, compared to $26.7 billion in the second quarter of 2023. It affirmed its already conservative guidance.

It revealed that MA rates have complicated its financial performance and that it would shutter some plans in geographies and has reduced benefits in others. It expects to lose about 5% of its projected 2024 enrollment next year, or about a few hundred thousand. It will increase its enrollment this year by about 225,000. Only Humana and CVS Aetna performed well on the enrollment front recently.

Its medical loss ratio (MLR) was 89.5% in the quarter, compared to 86.8% in the second quarter of 2023. Humana blames the increased utilization on the recent 2024 rule regarding prior authorization. MA plans must now follow traditional Medicare program rules, including honoring physicians’ certification for inpatient admission that someone needs a hospital stay and will remain in the hospital for at least two midnights.

Humana says that the changes will allow it to get back to a target 3% MA margin over time. It is basically flat right now.

Additional articles: https://www.modernhealthcare.com/insurance/humana-medicare-advantage-costs-jim-rechtin and https://www.healthcaredive.com/news/humana-membership-losses-medicare-advantage-plan-cuts/722619/ and https://www.beckerspayer.com/payer/humana-2-midnight-rule-driving-up-inpatient-costs.html and https://www.beckerspayer.com/payer/humana-expects-medicare-advantage-membership-to-decline-by-a-few-hundred-thousand.html and https://www.healthcarefinancenews.com/news/humana-logs-679-million-q2-profit

(Some articles may require a subscription.)

#medicareadvantage #humana #rates #margins

https://www.fiercehealthcare.com/payers/humana-posts-679m-q2-profit-it-faces-continued-medicare-advantage-headwinds

Read More »

Available Now

$30.00